nodes	percent_of_prediction	percent_of_DWPC	metapath
Bromocriptine—HTR2B—Sorafenib—thyroid cancer	0.223	0.381	CbGbCtD
Bromocriptine—HTR2C—Sorafenib—thyroid cancer	0.145	0.248	CbGbCtD
Bromocriptine—CYP1A2—Sorafenib—thyroid cancer	0.0529	0.0902	CbGbCtD
Bromocriptine—ABCB1—Sorafenib—thyroid cancer	0.0462	0.0789	CbGbCtD
Bromocriptine—CYP3A4—Vandetanib—thyroid cancer	0.0459	0.0784	CbGbCtD
Bromocriptine—ABCB1—Doxorubicin—thyroid cancer	0.028	0.0479	CbGbCtD
Bromocriptine—CYP3A4—Sorafenib—thyroid cancer	0.0277	0.0473	CbGbCtD
Bromocriptine—CYP3A4—Doxorubicin—thyroid cancer	0.0168	0.0287	CbGbCtD
Bromocriptine—Visual impairment—Vandetanib—thyroid cancer	0.0022	0.00806	CcSEcCtD
Bromocriptine—Eye disorder—Vandetanib—thyroid cancer	0.00213	0.00782	CcSEcCtD
Bromocriptine—Cardiac disorder—Vandetanib—thyroid cancer	0.00212	0.00776	CcSEcCtD
Bromocriptine—Angiopathy—Vandetanib—thyroid cancer	0.00207	0.00759	CcSEcCtD
Bromocriptine—Mediastinal disorder—Vandetanib—thyroid cancer	0.00205	0.00754	CcSEcCtD
Bromocriptine—Arrhythmia—Vandetanib—thyroid cancer	0.00204	0.00747	CcSEcCtD
Bromocriptine—Abdominal pain upper—Sorafenib—thyroid cancer	0.00203	0.00745	CcSEcCtD
Bromocriptine—Alopecia—Vandetanib—thyroid cancer	0.00201	0.00739	CcSEcCtD
Bromocriptine—Mental disorder—Vandetanib—thyroid cancer	0.002	0.00733	CcSEcCtD
Bromocriptine—Nasopharyngitis—Sorafenib—thyroid cancer	0.00199	0.00729	CcSEcCtD
Bromocriptine—Dysgeusia—Vandetanib—thyroid cancer	0.00194	0.00713	CcSEcCtD
Bromocriptine—Dysphagia—Sorafenib—thyroid cancer	0.00192	0.00705	CcSEcCtD
Bromocriptine—Muscle spasms—Vandetanib—thyroid cancer	0.00191	0.007	CcSEcCtD
Bromocriptine—Vision blurred—Vandetanib—thyroid cancer	0.00187	0.00686	CcSEcCtD
Bromocriptine—Abdominal discomfort—Sorafenib—thyroid cancer	0.00184	0.00676	CcSEcCtD
Bromocriptine—Loss of consciousness—Vandetanib—thyroid cancer	0.00174	0.0064	CcSEcCtD
Bromocriptine—Convulsion—Vandetanib—thyroid cancer	0.00172	0.00631	CcSEcCtD
Bromocriptine—Hypertension—Vandetanib—thyroid cancer	0.00171	0.00629	CcSEcCtD
Bromocriptine—Acute coronary syndrome—Sorafenib—thyroid cancer	0.00169	0.0062	CcSEcCtD
Bromocriptine—Anxiety—Vandetanib—thyroid cancer	0.00168	0.00618	CcSEcCtD
Bromocriptine—Myocardial infarction—Sorafenib—thyroid cancer	0.00168	0.00616	CcSEcCtD
Bromocriptine—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00168	0.00616	CcSEcCtD
Bromocriptine—Dry mouth—Vandetanib—thyroid cancer	0.00165	0.00606	CcSEcCtD
Bromocriptine—Burning sensation—Epirubicin—thyroid cancer	0.00163	0.00598	CcSEcCtD
Bromocriptine—Oedema—Vandetanib—thyroid cancer	0.00162	0.00594	CcSEcCtD
Bromocriptine—Infection—Vandetanib—thyroid cancer	0.00161	0.0059	CcSEcCtD
Bromocriptine—Nervous system disorder—Vandetanib—thyroid cancer	0.00159	0.00583	CcSEcCtD
Bromocriptine—Skin disorder—Vandetanib—thyroid cancer	0.00157	0.00577	CcSEcCtD
Bromocriptine—Dermatitis atopic—Epirubicin—thyroid cancer	0.00153	0.00561	CcSEcCtD
Bromocriptine—Connective tissue disorder—Sorafenib—thyroid cancer	0.00151	0.00555	CcSEcCtD
Bromocriptine—Burning sensation—Doxorubicin—thyroid cancer	0.00151	0.00553	CcSEcCtD
Bromocriptine—Pleural effusion—Epirubicin—thyroid cancer	0.00148	0.00542	CcSEcCtD
Bromocriptine—Amblyopia—Epirubicin—thyroid cancer	0.00147	0.00538	CcSEcCtD
Bromocriptine—Insomnia—Vandetanib—thyroid cancer	0.00146	0.00538	CcSEcCtD
Bromocriptine—Paraesthesia—Vandetanib—thyroid cancer	0.00145	0.00534	CcSEcCtD
Bromocriptine—Dyspnoea—Vandetanib—thyroid cancer	0.00144	0.0053	CcSEcCtD
Bromocriptine—Tinnitus—Sorafenib—thyroid cancer	0.00143	0.00526	CcSEcCtD
Bromocriptine—Cardiac disorder—Sorafenib—thyroid cancer	0.00143	0.00524	CcSEcCtD
Bromocriptine—Dyspepsia—Vandetanib—thyroid cancer	0.00143	0.00523	CcSEcCtD
Bromocriptine—Dermatitis atopic—Doxorubicin—thyroid cancer	0.00141	0.00519	CcSEcCtD
Bromocriptine—Decreased appetite—Vandetanib—thyroid cancer	0.00141	0.00517	CcSEcCtD
Bromocriptine—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.0014	0.00513	CcSEcCtD
Bromocriptine—Fatigue—Vandetanib—thyroid cancer	0.0014	0.00512	CcSEcCtD
Bromocriptine—Angiopathy—Sorafenib—thyroid cancer	0.00139	0.00512	CcSEcCtD
Bromocriptine—Mediastinal disorder—Sorafenib—thyroid cancer	0.00139	0.00509	CcSEcCtD
Bromocriptine—Constipation—Vandetanib—thyroid cancer	0.00138	0.00508	CcSEcCtD
Bromocriptine—Arrhythmia—Sorafenib—thyroid cancer	0.00137	0.00504	CcSEcCtD
Bromocriptine—Pleural effusion—Doxorubicin—thyroid cancer	0.00137	0.00502	CcSEcCtD
Bromocriptine—Alopecia—Sorafenib—thyroid cancer	0.00136	0.00499	CcSEcCtD
Bromocriptine—Amblyopia—Doxorubicin—thyroid cancer	0.00136	0.00498	CcSEcCtD
Bromocriptine—Mental disorder—Sorafenib—thyroid cancer	0.00135	0.00494	CcSEcCtD
Bromocriptine—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00132	0.00486	CcSEcCtD
Bromocriptine—Delirium—Epirubicin—thyroid cancer	0.00132	0.00483	CcSEcCtD
Bromocriptine—Dysgeusia—Sorafenib—thyroid cancer	0.00131	0.00481	CcSEcCtD
Bromocriptine—Muscle spasms—Sorafenib—thyroid cancer	0.00129	0.00472	CcSEcCtD
Bromocriptine—Body temperature increased—Vandetanib—thyroid cancer	0.00128	0.0047	CcSEcCtD
Bromocriptine—Abdominal pain—Vandetanib—thyroid cancer	0.00128	0.0047	CcSEcCtD
Bromocriptine—Delirium—Doxorubicin—thyroid cancer	0.00122	0.00447	CcSEcCtD
Bromocriptine—Dyskinesia—Epirubicin—thyroid cancer	0.0012	0.00442	CcSEcCtD
Bromocriptine—Syncope—Sorafenib—thyroid cancer	0.0012	0.00441	CcSEcCtD
Bromocriptine—Loss of consciousness—Sorafenib—thyroid cancer	0.00118	0.00432	CcSEcCtD
Bromocriptine—Asthenia—Vandetanib—thyroid cancer	0.00116	0.00426	CcSEcCtD
Bromocriptine—Hypertension—Sorafenib—thyroid cancer	0.00116	0.00424	CcSEcCtD
Bromocriptine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00113	0.00415	CcSEcCtD
Bromocriptine—Ventricular tachycardia—Epirubicin—thyroid cancer	0.00113	0.00415	CcSEcCtD
Bromocriptine—Dry mouth—Sorafenib—thyroid cancer	0.00111	0.00409	CcSEcCtD
Bromocriptine—Dyskinesia—Doxorubicin—thyroid cancer	0.00111	0.00409	CcSEcCtD
Bromocriptine—Diarrhoea—Vandetanib—thyroid cancer	0.00111	0.00407	CcSEcCtD
Bromocriptine—Infection—Sorafenib—thyroid cancer	0.00109	0.00398	CcSEcCtD
Bromocriptine—Shock—Sorafenib—thyroid cancer	0.00107	0.00394	CcSEcCtD
Bromocriptine—Nervous system disorder—Sorafenib—thyroid cancer	0.00107	0.00393	CcSEcCtD
Bromocriptine—Dizziness—Vandetanib—thyroid cancer	0.00107	0.00393	CcSEcCtD
Bromocriptine—Skin disorder—Sorafenib—thyroid cancer	0.00106	0.00389	CcSEcCtD
Bromocriptine—Ventricular tachycardia—Doxorubicin—thyroid cancer	0.00105	0.00384	CcSEcCtD
Bromocriptine—Anorexia—Sorafenib—thyroid cancer	0.00104	0.00382	CcSEcCtD
Bromocriptine—Cramps of lower extremities—Epirubicin—thyroid cancer	0.00104	0.00382	CcSEcCtD
Bromocriptine—Vomiting—Vandetanib—thyroid cancer	0.00103	0.00378	CcSEcCtD
Bromocriptine—Rash—Vandetanib—thyroid cancer	0.00102	0.00375	CcSEcCtD
Bromocriptine—Dermatitis—Vandetanib—thyroid cancer	0.00102	0.00374	CcSEcCtD
Bromocriptine—Headache—Vandetanib—thyroid cancer	0.00101	0.00372	CcSEcCtD
Bromocriptine—Dyspnoea—Sorafenib—thyroid cancer	0.000974	0.00357	CcSEcCtD
Bromocriptine—Nausea—Vandetanib—thyroid cancer	0.000962	0.00353	CcSEcCtD
Bromocriptine—Cramps of lower extremities—Doxorubicin—thyroid cancer	0.000962	0.00353	CcSEcCtD
Bromocriptine—Dyspepsia—Sorafenib—thyroid cancer	0.000961	0.00353	CcSEcCtD
Bromocriptine—Decreased appetite—Sorafenib—thyroid cancer	0.00095	0.00349	CcSEcCtD
Bromocriptine—Diabetes mellitus—Epirubicin—thyroid cancer	0.000944	0.00347	CcSEcCtD
Bromocriptine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000943	0.00346	CcSEcCtD
Bromocriptine—Fatigue—Sorafenib—thyroid cancer	0.000942	0.00346	CcSEcCtD
Bromocriptine—Constipation—Sorafenib—thyroid cancer	0.000934	0.00343	CcSEcCtD
Bromocriptine—Cardiac failure congestive—Epirubicin—thyroid cancer	0.000906	0.00332	CcSEcCtD
Bromocriptine—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000893	0.00328	CcSEcCtD
Bromocriptine—Diabetes mellitus—Doxorubicin—thyroid cancer	0.000874	0.00321	CcSEcCtD
Bromocriptine—Urticaria—Sorafenib—thyroid cancer	0.000868	0.00319	CcSEcCtD
Bromocriptine—Abdominal pain—Sorafenib—thyroid cancer	0.000863	0.00317	CcSEcCtD
Bromocriptine—Body temperature increased—Sorafenib—thyroid cancer	0.000863	0.00317	CcSEcCtD
Bromocriptine—Hypoglycaemia—Epirubicin—thyroid cancer	0.000842	0.00309	CcSEcCtD
Bromocriptine—Cerebrovascular accident—Epirubicin—thyroid cancer	0.000838	0.00308	CcSEcCtD
Bromocriptine—Lethargy—Epirubicin—thyroid cancer	0.000838	0.00308	CcSEcCtD
Bromocriptine—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.000838	0.00308	CcSEcCtD
Bromocriptine—Diplopia—Epirubicin—thyroid cancer	0.000821	0.00301	CcSEcCtD
Bromocriptine—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	0.000821	0.00301	CcSEcCtD
Bromocriptine—Asthenia—Sorafenib—thyroid cancer	0.000784	0.00288	CcSEcCtD
Bromocriptine—Hypoglycaemia—Doxorubicin—thyroid cancer	0.000779	0.00286	CcSEcCtD
Bromocriptine—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.000776	0.00285	CcSEcCtD
Bromocriptine—Lethargy—Doxorubicin—thyroid cancer	0.000776	0.00285	CcSEcCtD
Bromocriptine—Ataxia—Epirubicin—thyroid cancer	0.000772	0.00283	CcSEcCtD
Bromocriptine—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	0.00076	0.00279	CcSEcCtD
Bromocriptine—Diplopia—Doxorubicin—thyroid cancer	0.00076	0.00279	CcSEcCtD
Bromocriptine—Orthostatic hypotension—Epirubicin—thyroid cancer	0.00075	0.00275	CcSEcCtD
Bromocriptine—Abdominal pain upper—Epirubicin—thyroid cancer	0.00075	0.00275	CcSEcCtD
Bromocriptine—Diarrhoea—Sorafenib—thyroid cancer	0.000747	0.00274	CcSEcCtD
Bromocriptine—Nasopharyngitis—Epirubicin—thyroid cancer	0.000734	0.0027	CcSEcCtD
Bromocriptine—Dizziness—Sorafenib—thyroid cancer	0.000722	0.00265	CcSEcCtD
Bromocriptine—Ataxia—Doxorubicin—thyroid cancer	0.000715	0.00262	CcSEcCtD
Bromocriptine—Dysphagia—Epirubicin—thyroid cancer	0.00071	0.00261	CcSEcCtD
Bromocriptine—Influenza—Epirubicin—thyroid cancer	0.00071	0.00261	CcSEcCtD
Bromocriptine—Vomiting—Sorafenib—thyroid cancer	0.000694	0.00255	CcSEcCtD
Bromocriptine—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000694	0.00255	CcSEcCtD
Bromocriptine—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000694	0.00255	CcSEcCtD
Bromocriptine—Rash—Sorafenib—thyroid cancer	0.000689	0.00253	CcSEcCtD
Bromocriptine—Dermatitis—Sorafenib—thyroid cancer	0.000688	0.00253	CcSEcCtD
Bromocriptine—Headache—Sorafenib—thyroid cancer	0.000684	0.00251	CcSEcCtD
Bromocriptine—Nasopharyngitis—Doxorubicin—thyroid cancer	0.00068	0.00249	CcSEcCtD
Bromocriptine—Influenza—Doxorubicin—thyroid cancer	0.000657	0.00241	CcSEcCtD
Bromocriptine—Dysphagia—Doxorubicin—thyroid cancer	0.000657	0.00241	CcSEcCtD
Bromocriptine—Pollakiuria—Epirubicin—thyroid cancer	0.000656	0.00241	CcSEcCtD
Bromocriptine—Nausea—Sorafenib—thyroid cancer	0.000649	0.00238	CcSEcCtD
Bromocriptine—Drowsiness—Epirubicin—thyroid cancer	0.000633	0.00232	CcSEcCtD
Bromocriptine—Pollakiuria—Doxorubicin—thyroid cancer	0.000607	0.00223	CcSEcCtD
Bromocriptine—Sinusitis—Epirubicin—thyroid cancer	0.000594	0.00218	CcSEcCtD
Bromocriptine—Drowsiness—Doxorubicin—thyroid cancer	0.000586	0.00215	CcSEcCtD
Bromocriptine—Bradycardia—Epirubicin—thyroid cancer	0.000578	0.00212	CcSEcCtD
Bromocriptine—Rhinitis—Epirubicin—thyroid cancer	0.00057	0.00209	CcSEcCtD
Bromocriptine—Hypoaesthesia—Epirubicin—thyroid cancer	0.000565	0.00208	CcSEcCtD
Bromocriptine—Oedema peripheral—Epirubicin—thyroid cancer	0.00056	0.00205	CcSEcCtD
Bromocriptine—Connective tissue disorder—Epirubicin—thyroid cancer	0.000558	0.00205	CcSEcCtD
Bromocriptine—Sinusitis—Doxorubicin—thyroid cancer	0.000549	0.00202	CcSEcCtD
Bromocriptine—Visual impairment—Epirubicin—thyroid cancer	0.000548	0.00201	CcSEcCtD
Bromocriptine—Bradycardia—Doxorubicin—thyroid cancer	0.000535	0.00196	CcSEcCtD
Bromocriptine—Eye disorder—Epirubicin—thyroid cancer	0.000531	0.00195	CcSEcCtD
Bromocriptine—Tinnitus—Epirubicin—thyroid cancer	0.00053	0.00194	CcSEcCtD
Bromocriptine—Cardiac disorder—Epirubicin—thyroid cancer	0.000527	0.00194	CcSEcCtD
Bromocriptine—Rhinitis—Doxorubicin—thyroid cancer	0.000527	0.00193	CcSEcCtD
Bromocriptine—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000523	0.00192	CcSEcCtD
Bromocriptine—Oedema peripheral—Doxorubicin—thyroid cancer	0.000518	0.0019	CcSEcCtD
Bromocriptine—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000517	0.0019	CcSEcCtD
Bromocriptine—Angiopathy—Epirubicin—thyroid cancer	0.000516	0.00189	CcSEcCtD
Bromocriptine—Mediastinal disorder—Epirubicin—thyroid cancer	0.000512	0.00188	CcSEcCtD
Bromocriptine—Arrhythmia—Epirubicin—thyroid cancer	0.000508	0.00186	CcSEcCtD
Bromocriptine—Visual impairment—Doxorubicin—thyroid cancer	0.000507	0.00186	CcSEcCtD
Bromocriptine—Alopecia—Epirubicin—thyroid cancer	0.000502	0.00184	CcSEcCtD
Bromocriptine—Mental disorder—Epirubicin—thyroid cancer	0.000498	0.00183	CcSEcCtD
Bromocriptine—Eye disorder—Doxorubicin—thyroid cancer	0.000491	0.0018	CcSEcCtD
Bromocriptine—Tinnitus—Doxorubicin—thyroid cancer	0.00049	0.0018	CcSEcCtD
Bromocriptine—Cardiac disorder—Doxorubicin—thyroid cancer	0.000488	0.00179	CcSEcCtD
Bromocriptine—Tension—Epirubicin—thyroid cancer	0.000485	0.00178	CcSEcCtD
Bromocriptine—Dysgeusia—Epirubicin—thyroid cancer	0.000484	0.00178	CcSEcCtD
Bromocriptine—Nervousness—Epirubicin—thyroid cancer	0.00048	0.00176	CcSEcCtD
Bromocriptine—Angiopathy—Doxorubicin—thyroid cancer	0.000477	0.00175	CcSEcCtD
Bromocriptine—Muscle spasms—Epirubicin—thyroid cancer	0.000476	0.00175	CcSEcCtD
Bromocriptine—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000474	0.00174	CcSEcCtD
Bromocriptine—Arrhythmia—Doxorubicin—thyroid cancer	0.00047	0.00172	CcSEcCtD
Bromocriptine—Vision blurred—Epirubicin—thyroid cancer	0.000466	0.00171	CcSEcCtD
Bromocriptine—Alopecia—Doxorubicin—thyroid cancer	0.000465	0.00171	CcSEcCtD
Bromocriptine—Mental disorder—Doxorubicin—thyroid cancer	0.000461	0.00169	CcSEcCtD
Bromocriptine—Agitation—Epirubicin—thyroid cancer	0.000455	0.00167	CcSEcCtD
Bromocriptine—Tension—Doxorubicin—thyroid cancer	0.000449	0.00165	CcSEcCtD
Bromocriptine—Dysgeusia—Doxorubicin—thyroid cancer	0.000448	0.00165	CcSEcCtD
Bromocriptine—Nervousness—Doxorubicin—thyroid cancer	0.000445	0.00163	CcSEcCtD
Bromocriptine—Vertigo—Epirubicin—thyroid cancer	0.000444	0.00163	CcSEcCtD
Bromocriptine—Syncope—Epirubicin—thyroid cancer	0.000444	0.00163	CcSEcCtD
Bromocriptine—Muscle spasms—Doxorubicin—thyroid cancer	0.00044	0.00162	CcSEcCtD
Bromocriptine—Loss of consciousness—Epirubicin—thyroid cancer	0.000435	0.0016	CcSEcCtD
Bromocriptine—Vision blurred—Doxorubicin—thyroid cancer	0.000431	0.00158	CcSEcCtD
Bromocriptine—Convulsion—Epirubicin—thyroid cancer	0.000429	0.00157	CcSEcCtD
Bromocriptine—Hypertension—Epirubicin—thyroid cancer	0.000427	0.00157	CcSEcCtD
Bromocriptine—Agitation—Doxorubicin—thyroid cancer	0.000421	0.00154	CcSEcCtD
Bromocriptine—Anxiety—Epirubicin—thyroid cancer	0.00042	0.00154	CcSEcCtD
Bromocriptine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000418	0.00153	CcSEcCtD
Bromocriptine—Dry mouth—Epirubicin—thyroid cancer	0.000412	0.00151	CcSEcCtD
Bromocriptine—Vertigo—Doxorubicin—thyroid cancer	0.000411	0.00151	CcSEcCtD
Bromocriptine—Syncope—Doxorubicin—thyroid cancer	0.00041	0.00151	CcSEcCtD
Bromocriptine—Confusional state—Epirubicin—thyroid cancer	0.000407	0.00149	CcSEcCtD
Bromocriptine—Oedema—Epirubicin—thyroid cancer	0.000404	0.00148	CcSEcCtD
Bromocriptine—Loss of consciousness—Doxorubicin—thyroid cancer	0.000402	0.00148	CcSEcCtD
Bromocriptine—Infection—Epirubicin—thyroid cancer	0.000401	0.00147	CcSEcCtD
Bromocriptine—Shock—Epirubicin—thyroid cancer	0.000397	0.00146	CcSEcCtD
Bromocriptine—Convulsion—Doxorubicin—thyroid cancer	0.000397	0.00146	CcSEcCtD
Bromocriptine—Nervous system disorder—Epirubicin—thyroid cancer	0.000396	0.00145	CcSEcCtD
Bromocriptine—Hypertension—Doxorubicin—thyroid cancer	0.000395	0.00145	CcSEcCtD
Bromocriptine—Tachycardia—Epirubicin—thyroid cancer	0.000394	0.00145	CcSEcCtD
Bromocriptine—Skin disorder—Epirubicin—thyroid cancer	0.000392	0.00144	CcSEcCtD
Bromocriptine—Anxiety—Doxorubicin—thyroid cancer	0.000388	0.00143	CcSEcCtD
Bromocriptine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000387	0.00142	CcSEcCtD
Bromocriptine—Anorexia—Epirubicin—thyroid cancer	0.000385	0.00141	CcSEcCtD
Bromocriptine—Dry mouth—Doxorubicin—thyroid cancer	0.000381	0.0014	CcSEcCtD
Bromocriptine—Hypotension—Epirubicin—thyroid cancer	0.000377	0.00138	CcSEcCtD
Bromocriptine—Confusional state—Doxorubicin—thyroid cancer	0.000377	0.00138	CcSEcCtD
Bromocriptine—Oedema—Doxorubicin—thyroid cancer	0.000374	0.00137	CcSEcCtD
Bromocriptine—Infection—Doxorubicin—thyroid cancer	0.000371	0.00136	CcSEcCtD
Bromocriptine—Shock—Doxorubicin—thyroid cancer	0.000367	0.00135	CcSEcCtD
Bromocriptine—Nervous system disorder—Doxorubicin—thyroid cancer	0.000366	0.00134	CcSEcCtD
Bromocriptine—Insomnia—Epirubicin—thyroid cancer	0.000365	0.00134	CcSEcCtD
Bromocriptine—Tachycardia—Doxorubicin—thyroid cancer	0.000365	0.00134	CcSEcCtD
Bromocriptine—Skin disorder—Doxorubicin—thyroid cancer	0.000363	0.00133	CcSEcCtD
Bromocriptine—Paraesthesia—Epirubicin—thyroid cancer	0.000362	0.00133	CcSEcCtD
Bromocriptine—Dyspnoea—Epirubicin—thyroid cancer	0.00036	0.00132	CcSEcCtD
Bromocriptine—Somnolence—Epirubicin—thyroid cancer	0.000359	0.00132	CcSEcCtD
Bromocriptine—Anorexia—Doxorubicin—thyroid cancer	0.000356	0.00131	CcSEcCtD
Bromocriptine—Dyspepsia—Epirubicin—thyroid cancer	0.000355	0.0013	CcSEcCtD
Bromocriptine—Decreased appetite—Epirubicin—thyroid cancer	0.000351	0.00129	CcSEcCtD
Bromocriptine—Hypotension—Doxorubicin—thyroid cancer	0.000349	0.00128	CcSEcCtD
Bromocriptine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000349	0.00128	CcSEcCtD
Bromocriptine—Fatigue—Epirubicin—thyroid cancer	0.000348	0.00128	CcSEcCtD
Bromocriptine—Constipation—Epirubicin—thyroid cancer	0.000345	0.00127	CcSEcCtD
Bromocriptine—Insomnia—Doxorubicin—thyroid cancer	0.000338	0.00124	CcSEcCtD
Bromocriptine—Paraesthesia—Doxorubicin—thyroid cancer	0.000335	0.00123	CcSEcCtD
Bromocriptine—Dyspnoea—Doxorubicin—thyroid cancer	0.000333	0.00122	CcSEcCtD
Bromocriptine—Feeling abnormal—Epirubicin—thyroid cancer	0.000333	0.00122	CcSEcCtD
Bromocriptine—Somnolence—Doxorubicin—thyroid cancer	0.000332	0.00122	CcSEcCtD
Bromocriptine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.00033	0.00121	CcSEcCtD
Bromocriptine—Dyspepsia—Doxorubicin—thyroid cancer	0.000329	0.00121	CcSEcCtD
Bromocriptine—Decreased appetite—Doxorubicin—thyroid cancer	0.000325	0.00119	CcSEcCtD
Bromocriptine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000322	0.00118	CcSEcCtD
Bromocriptine—Fatigue—Doxorubicin—thyroid cancer	0.000322	0.00118	CcSEcCtD
Bromocriptine—Urticaria—Epirubicin—thyroid cancer	0.000321	0.00118	CcSEcCtD
Bromocriptine—Constipation—Doxorubicin—thyroid cancer	0.000319	0.00117	CcSEcCtD
Bromocriptine—Body temperature increased—Epirubicin—thyroid cancer	0.000319	0.00117	CcSEcCtD
Bromocriptine—Abdominal pain—Epirubicin—thyroid cancer	0.000319	0.00117	CcSEcCtD
Bromocriptine—Feeling abnormal—Doxorubicin—thyroid cancer	0.000308	0.00113	CcSEcCtD
Bromocriptine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000305	0.00112	CcSEcCtD
Bromocriptine—Urticaria—Doxorubicin—thyroid cancer	0.000297	0.00109	CcSEcCtD
Bromocriptine—Body temperature increased—Doxorubicin—thyroid cancer	0.000295	0.00108	CcSEcCtD
Bromocriptine—Abdominal pain—Doxorubicin—thyroid cancer	0.000295	0.00108	CcSEcCtD
Bromocriptine—Asthenia—Epirubicin—thyroid cancer	0.00029	0.00106	CcSEcCtD
Bromocriptine—Diarrhoea—Epirubicin—thyroid cancer	0.000276	0.00101	CcSEcCtD
Bromocriptine—Asthenia—Doxorubicin—thyroid cancer	0.000268	0.000984	CcSEcCtD
Bromocriptine—Dizziness—Epirubicin—thyroid cancer	0.000267	0.00098	CcSEcCtD
Bromocriptine—HTR7—neck—thyroid cancer	0.000267	0.0605	CbGeAlD
Bromocriptine—Vomiting—Epirubicin—thyroid cancer	0.000257	0.000942	CcSEcCtD
Bromocriptine—Diarrhoea—Doxorubicin—thyroid cancer	0.000256	0.000938	CcSEcCtD
Bromocriptine—Rash—Epirubicin—thyroid cancer	0.000255	0.000934	CcSEcCtD
Bromocriptine—Dermatitis—Epirubicin—thyroid cancer	0.000254	0.000933	CcSEcCtD
Bromocriptine—Headache—Epirubicin—thyroid cancer	0.000253	0.000928	CcSEcCtD
Bromocriptine—DRD3—head—thyroid cancer	0.000252	0.0571	CbGeAlD
Bromocriptine—Dizziness—Doxorubicin—thyroid cancer	0.000247	0.000907	CcSEcCtD
Bromocriptine—HTR6—head—thyroid cancer	0.000242	0.0549	CbGeAlD
Bromocriptine—Nausea—Epirubicin—thyroid cancer	0.00024	0.00088	CcSEcCtD
Bromocriptine—Vomiting—Doxorubicin—thyroid cancer	0.000237	0.000872	CcSEcCtD
Bromocriptine—DRD5—head—thyroid cancer	0.000236	0.0535	CbGeAlD
Bromocriptine—Rash—Doxorubicin—thyroid cancer	0.000236	0.000864	CcSEcCtD
Bromocriptine—Dermatitis—Doxorubicin—thyroid cancer	0.000235	0.000864	CcSEcCtD
Bromocriptine—Headache—Doxorubicin—thyroid cancer	0.000234	0.000859	CcSEcCtD
Bromocriptine—Nausea—Doxorubicin—thyroid cancer	0.000222	0.000814	CcSEcCtD
Bromocriptine—ADRA1B—head—thyroid cancer	0.000193	0.0438	CbGeAlD
Bromocriptine—ADRA1D—head—thyroid cancer	0.000189	0.0429	CbGeAlD
Bromocriptine—DRD1—head—thyroid cancer	0.00018	0.0409	CbGeAlD
Bromocriptine—HTR2A—neck—thyroid cancer	0.000166	0.0377	CbGeAlD
Bromocriptine—HTR7—trachea—thyroid cancer	0.00016	0.0364	CbGeAlD
Bromocriptine—HTR2B—thyroid gland—thyroid cancer	0.000148	0.0336	CbGeAlD
Bromocriptine—ADRA2C—trachea—thyroid cancer	0.000148	0.0334	CbGeAlD
Bromocriptine—HTR1B—head—thyroid cancer	0.000146	0.0331	CbGeAlD
Bromocriptine—HTR1D—head—thyroid cancer	0.000141	0.0321	CbGeAlD
Bromocriptine—HTR2C—head—thyroid cancer	0.00014	0.0317	CbGeAlD
Bromocriptine—ADRB1—head—thyroid cancer	0.000137	0.0312	CbGeAlD
Bromocriptine—HTR2B—head—thyroid cancer	0.000132	0.0298	CbGeAlD
Bromocriptine—HTR1A—head—thyroid cancer	0.000118	0.0267	CbGeAlD
Bromocriptine—ADRA2A—trachea—thyroid cancer	0.000118	0.0267	CbGeAlD
Bromocriptine—HTR7—head—thyroid cancer	0.000113	0.0255	CbGeAlD
Bromocriptine—ADRA1A—head—thyroid cancer	0.000109	0.0246	CbGeAlD
Bromocriptine—DRD2—head—thyroid cancer	0.000106	0.0241	CbGeAlD
Bromocriptine—ADRA2C—head—thyroid cancer	0.000104	0.0235	CbGeAlD
Bromocriptine—CYP1A2—thyroid gland—thyroid cancer	0.000101	0.023	CbGeAlD
Bromocriptine—HTR2A—trachea—thyroid cancer	0.0001	0.0227	CbGeAlD
Bromocriptine—ADRA2A—thyroid gland—thyroid cancer	9.31e-05	0.0211	CbGeAlD
Bromocriptine—HTR2B—lymph node—thyroid cancer	9.21e-05	0.0209	CbGeAlD
Bromocriptine—ADRA2A—head—thyroid cancer	8.26e-05	0.0187	CbGeAlD
Bromocriptine—ADRA2C—lymph node—thyroid cancer	7.25e-05	0.0164	CbGeAlD
Bromocriptine—HTR2A—head—thyroid cancer	7.02e-05	0.0159	CbGeAlD
Bromocriptine—ABCB1—trachea—thyroid cancer	6.56e-05	0.0149	CbGeAlD
Bromocriptine—ADRA2A—lymph node—thyroid cancer	5.78e-05	0.0131	CbGeAlD
Bromocriptine—ABCB1—thyroid gland—thyroid cancer	5.19e-05	0.0118	CbGeAlD
Bromocriptine—ABCB1—head—thyroid cancer	4.6e-05	0.0104	CbGeAlD
Bromocriptine—ABCB1—lymph node—thyroid cancer	3.22e-05	0.00731	CbGeAlD
Bromocriptine—ADRB1—Signaling Pathways—BRAF—thyroid cancer	2.31e-05	0.000168	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling by GPCR—HRAS—thyroid cancer	2.3e-05	0.000168	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—HIF1A—thyroid cancer	2.3e-05	0.000168	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—BRAF—thyroid cancer	2.29e-05	0.000167	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—TPR—thyroid cancer	2.29e-05	0.000167	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling by GPCR—NRAS—thyroid cancer	2.27e-05	0.000166	CbGpPWpGaD
Bromocriptine—HTR6—GPCR downstream signaling—AKT1—thyroid cancer	2.26e-05	0.000164	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling by GPCR—HRAS—thyroid cancer	2.26e-05	0.000164	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—HIF1A—thyroid cancer	2.26e-05	0.000164	CbGpPWpGaD
Bromocriptine—HTR7—GPCR downstream signaling—AKT1—thyroid cancer	2.26e-05	0.000164	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	2.25e-05	0.000164	CbGpPWpGaD
Bromocriptine—HTR1D—GPCR downstream signaling—AKT1—thyroid cancer	2.24e-05	0.000163	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling by GPCR—NRAS—thyroid cancer	2.24e-05	0.000163	CbGpPWpGaD
Bromocriptine—DRD4—Signaling by GPCR—HRAS—thyroid cancer	2.22e-05	0.000162	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—SLC5A5—thyroid cancer	2.22e-05	0.000162	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—BRAF—thyroid cancer	2.21e-05	0.000161	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—BRAF—thyroid cancer	2.2e-05	0.00016	CbGpPWpGaD
Bromocriptine—HTR1B—GPCR downstream signaling—AKT1—thyroid cancer	2.19e-05	0.00016	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—TERT—thyroid cancer	2.19e-05	0.00016	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—CCND1—thyroid cancer	2.18e-05	0.000159	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—CCND1—thyroid cancer	2.17e-05	0.000158	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—CCND1—thyroid cancer	2.16e-05	0.000157	CbGpPWpGaD
Bromocriptine—DRD4—GPCR downstream signaling—AKT1—thyroid cancer	2.16e-05	0.000157	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—BRAF—thyroid cancer	2.14e-05	0.000156	CbGpPWpGaD
Bromocriptine—ADRA2A—Metabolism—PPARG—thyroid cancer	2.13e-05	0.000155	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling by GPCR—HRAS—thyroid cancer	2.12e-05	0.000154	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—CCND1—thyroid cancer	2.12e-05	0.000154	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling by GPCR—KRAS—thyroid cancer	2.11e-05	0.000154	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—BRAF—thyroid cancer	2.1e-05	0.000153	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—PTEN—thyroid cancer	2.1e-05	0.000153	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—PTEN—thyroid cancer	2.1e-05	0.000153	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—HIF1A—thyroid cancer	2.1e-05	0.000153	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling by GPCR—KRAS—thyroid cancer	2.09e-05	0.000153	CbGpPWpGaD
Bromocriptine—DRD5—Signaling Pathways—KRAS—thyroid cancer	2.09e-05	0.000152	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—PTEN—thyroid cancer	2.09e-05	0.000152	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—CCND1—thyroid cancer	2.08e-05	0.000152	CbGpPWpGaD
Bromocriptine—ADRA2A—Hemostasis—AKT1—thyroid cancer	2.08e-05	0.000151	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.08e-05	0.000151	CbGpPWpGaD
Bromocriptine—ADRA2C—Metabolism—PTGS2—thyroid cancer	2.06e-05	0.00015	CbGpPWpGaD
Bromocriptine—DRD2—Signaling by GPCR—NRAS—thyroid cancer	2.06e-05	0.00015	CbGpPWpGaD
Bromocriptine—HTR2B—GPCR downstream signaling—AKT1—thyroid cancer	2.06e-05	0.00015	CbGpPWpGaD
Bromocriptine—HTR6—Signaling by GPCR—AKT1—thyroid cancer	2.05e-05	0.000149	CbGpPWpGaD
Bromocriptine—HTR7—Signaling by GPCR—AKT1—thyroid cancer	2.05e-05	0.000149	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—PTEN—thyroid cancer	2.04e-05	0.000149	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling by GPCR—AKT1—thyroid cancer	2.03e-05	0.000148	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling by GPCR—NRAS—thyroid cancer	2.03e-05	0.000148	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling by GPCR—KRAS—thyroid cancer	2.02e-05	0.000147	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling by GPCR—KRAS—thyroid cancer	2.01e-05	0.000147	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—PTEN—thyroid cancer	2.01e-05	0.000146	CbGpPWpGaD
Bromocriptine—DRD1—Signaling by GPCR—HRAS—thyroid cancer	2e-05	0.000146	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling by GPCR—AKT1—thyroid cancer	1.99e-05	0.000145	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—CCND1—thyroid cancer	1.99e-05	0.000145	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling by GPCR—NRAS—thyroid cancer	1.99e-05	0.000145	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling by GPCR—HRAS—thyroid cancer	1.97e-05	0.000144	CbGpPWpGaD
Bromocriptine—DRD3—Signaling by GPCR—HRAS—thyroid cancer	1.97e-05	0.000144	CbGpPWpGaD
Bromocriptine—DRD4—Signaling by GPCR—AKT1—thyroid cancer	1.96e-05	0.000143	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling by GPCR—KRAS—thyroid cancer	1.96e-05	0.000143	CbGpPWpGaD
Bromocriptine—DRD1—GPCR downstream signaling—AKT1—thyroid cancer	1.94e-05	0.000142	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—BRAF—thyroid cancer	1.94e-05	0.000141	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling by GPCR—KRAS—thyroid cancer	1.93e-05	0.00014	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—PTEN—thyroid cancer	1.92e-05	0.00014	CbGpPWpGaD
Bromocriptine—ADRA1D—GPCR downstream signaling—AKT1—thyroid cancer	1.92e-05	0.00014	CbGpPWpGaD
Bromocriptine—DRD3—GPCR downstream signaling—AKT1—thyroid cancer	1.92e-05	0.00014	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—BRAF—thyroid cancer	1.91e-05	0.000139	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—NRAS—thyroid cancer	1.87e-05	0.000137	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—CCND1—thyroid cancer	1.87e-05	0.000137	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—NRAS—thyroid cancer	1.87e-05	0.000136	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling by GPCR—AKT1—thyroid cancer	1.87e-05	0.000136	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—BRAF—thyroid cancer	1.87e-05	0.000136	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—RXRA—thyroid cancer	1.86e-05	0.000136	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—NRAS—thyroid cancer	1.86e-05	0.000136	CbGpPWpGaD
Bromocriptine—DRD5—Signaling Pathways—TP53—thyroid cancer	1.86e-05	0.000135	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—CCND1—thyroid cancer	1.85e-05	0.000135	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—CCND1—thyroid cancer	1.85e-05	0.000135	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling by GPCR—NRAS—thyroid cancer	1.85e-05	0.000135	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—NRAS—thyroid cancer	1.82e-05	0.000133	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.81e-05	0.000132	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—PTEN—thyroid cancer	1.81e-05	0.000132	CbGpPWpGaD
Bromocriptine—ADRA2C—Metabolism—PTEN—thyroid cancer	1.8e-05	0.000131	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling by GPCR—HRAS—thyroid cancer	1.8e-05	0.000131	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—NRAS—thyroid cancer	1.79e-05	0.000131	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—PTEN—thyroid cancer	1.78e-05	0.00013	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—PTEN—thyroid cancer	1.78e-05	0.00013	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling by GPCR—HRAS—thyroid cancer	1.78e-05	0.00013	CbGpPWpGaD
Bromocriptine—DRD5—Signaling Pathways—HRAS—thyroid cancer	1.78e-05	0.000129	CbGpPWpGaD
Bromocriptine—DRD2—Signaling by GPCR—KRAS—thyroid cancer	1.78e-05	0.000129	CbGpPWpGaD
Bromocriptine—DRD1—Signaling by GPCR—AKT1—thyroid cancer	1.76e-05	0.000129	CbGpPWpGaD
Bromocriptine—ADRB1—GPCR downstream signaling—AKT1—thyroid cancer	1.75e-05	0.000127	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling by GPCR—KRAS—thyroid cancer	1.75e-05	0.000127	CbGpPWpGaD
Bromocriptine—DRD3—Signaling by GPCR—AKT1—thyroid cancer	1.74e-05	0.000127	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling by GPCR—AKT1—thyroid cancer	1.74e-05	0.000127	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—BRAF—thyroid cancer	1.74e-05	0.000126	CbGpPWpGaD
Bromocriptine—ADRA2B—GPCR downstream signaling—AKT1—thyroid cancer	1.73e-05	0.000126	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling by GPCR—HRAS—thyroid cancer	1.72e-05	0.000125	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.71e-05	0.000125	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—NRAS—thyroid cancer	1.71e-05	0.000125	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling by GPCR—KRAS—thyroid cancer	1.71e-05	0.000125	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling by GPCR—HRAS—thyroid cancer	1.71e-05	0.000125	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—CCND1—thyroid cancer	1.69e-05	0.000123	CbGpPWpGaD
Bromocriptine—ADRA2A—Metabolism—PTGS2—thyroid cancer	1.68e-05	0.000122	CbGpPWpGaD
Bromocriptine—HTR1A—GPCR downstream signaling—AKT1—thyroid cancer	1.67e-05	0.000122	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—CCND1—thyroid cancer	1.67e-05	0.000122	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling by GPCR—HRAS—thyroid cancer	1.66e-05	0.000121	CbGpPWpGaD
Bromocriptine—HTR2C—GPCR downstream signaling—AKT1—thyroid cancer	1.66e-05	0.000121	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling by GPCR—HRAS—thyroid cancer	1.64e-05	0.000119	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—PTEN—thyroid cancer	1.63e-05	0.000118	CbGpPWpGaD
Bromocriptine—ADRA2C—GPCR downstream signaling—AKT1—thyroid cancer	1.62e-05	0.000118	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—NRAS—thyroid cancer	1.61e-05	0.000118	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—KRAS—thyroid cancer	1.61e-05	0.000118	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—KRAS—thyroid cancer	1.61e-05	0.000117	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—CCND1—thyroid cancer	1.61e-05	0.000117	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—PTEN—thyroid cancer	1.61e-05	0.000117	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—CCND1—thyroid cancer	1.6e-05	0.000117	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—KRAS—thyroid cancer	1.6e-05	0.000117	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—NRAS—thyroid cancer	1.59e-05	0.000116	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—NRAS—thyroid cancer	1.59e-05	0.000116	CbGpPWpGaD
Bromocriptine—ADRA1B—GPCR downstream signaling—AKT1—thyroid cancer	1.59e-05	0.000116	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling by GPCR—KRAS—thyroid cancer	1.59e-05	0.000116	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling by GPCR—AKT1—thyroid cancer	1.59e-05	0.000116	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling by GPCR—AKT1—thyroid cancer	1.57e-05	0.000115	CbGpPWpGaD
Bromocriptine—DRD5—Signaling Pathways—AKT1—thyroid cancer	1.57e-05	0.000114	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—KRAS—thyroid cancer	1.57e-05	0.000114	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—CCND1—thyroid cancer	1.56e-05	0.000114	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—PTEN—thyroid cancer	1.56e-05	0.000113	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—PTEN—thyroid cancer	1.55e-05	0.000113	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—KRAS—thyroid cancer	1.54e-05	0.000112	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—CCND1—thyroid cancer	1.53e-05	0.000112	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling by GPCR—AKT1—thyroid cancer	1.52e-05	0.000111	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling by GPCR—AKT1—thyroid cancer	1.51e-05	0.00011	CbGpPWpGaD
Bromocriptine—DRD2—Signaling by GPCR—HRAS—thyroid cancer	1.51e-05	0.00011	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—PTEN—thyroid cancer	1.51e-05	0.00011	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling by GPCR—HRAS—thyroid cancer	1.48e-05	0.000108	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—PTEN—thyroid cancer	1.48e-05	0.000108	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—PPARG—thyroid cancer	1.47e-05	0.000107	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—KRAS—thyroid cancer	1.47e-05	0.000107	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling by GPCR—AKT1—thyroid cancer	1.47e-05	0.000107	CbGpPWpGaD
Bromocriptine—DRD2—GPCR downstream signaling—AKT1—thyroid cancer	1.47e-05	0.000107	CbGpPWpGaD
Bromocriptine—ADRA2A—Metabolism—PTEN—thyroid cancer	1.46e-05	0.000107	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling by GPCR—HRAS—thyroid cancer	1.45e-05	0.000106	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—NRAS—thyroid cancer	1.45e-05	0.000106	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling by GPCR—AKT1—thyroid cancer	1.45e-05	0.000105	CbGpPWpGaD
Bromocriptine—HTR2A—GPCR downstream signaling—AKT1—thyroid cancer	1.44e-05	0.000105	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—RXRA—thyroid cancer	1.44e-05	0.000105	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—NRAS—thyroid cancer	1.44e-05	0.000105	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—TP53—thyroid cancer	1.43e-05	0.000105	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—TP53—thyroid cancer	1.43e-05	0.000104	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—TP53—thyroid cancer	1.42e-05	0.000104	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—CCND1—thyroid cancer	1.42e-05	0.000103	CbGpPWpGaD
Bromocriptine—ADRA1A—GPCR downstream signaling—AKT1—thyroid cancer	1.41e-05	0.000103	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—TP53—thyroid cancer	1.39e-05	0.000102	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—CCND1—thyroid cancer	1.39e-05	0.000101	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—KRAS—thyroid cancer	1.39e-05	0.000101	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—NRAS—thyroid cancer	1.39e-05	0.000101	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—NRAS—thyroid cancer	1.38e-05	0.000101	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—HRAS—thyroid cancer	1.37e-05	9.99e-05	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—TP53—thyroid cancer	1.37e-05	9.99e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—KRAS—thyroid cancer	1.37e-05	9.99e-05	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—KRAS—thyroid cancer	1.37e-05	9.99e-05	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—HRAS—thyroid cancer	1.37e-05	9.98e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—PTEN—thyroid cancer	1.37e-05	9.95e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—CCND1—thyroid cancer	1.36e-05	9.93e-05	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—HRAS—thyroid cancer	1.36e-05	9.92e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling by GPCR—HRAS—thyroid cancer	1.35e-05	9.84e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—PTEN—thyroid cancer	1.34e-05	9.79e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—NRAS—thyroid cancer	1.34e-05	9.78e-05	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—HRAS—thyroid cancer	1.33e-05	9.71e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling by GPCR—AKT1—thyroid cancer	1.33e-05	9.71e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—NRAS—thyroid cancer	1.32e-05	9.63e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—PTEN—thyroid cancer	1.32e-05	9.59e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—GPCR downstream signaling—AKT1—thyroid cancer	1.31e-05	9.57e-05	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—HRAS—thyroid cancer	1.31e-05	9.56e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling by GPCR—AKT1—thyroid cancer	1.31e-05	9.55e-05	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—TP53—thyroid cancer	1.31e-05	9.54e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling by GPCR—AKT1—thyroid cancer	1.28e-05	9.35e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—CCND1—thyroid cancer	1.27e-05	9.23e-05	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—HRAS—thyroid cancer	1.25e-05	9.12e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—KRAS—thyroid cancer	1.25e-05	9.1e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—KRAS—thyroid cancer	1.24e-05	9.02e-05	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—TP53—thyroid cancer	1.23e-05	9e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—PTEN—thyroid cancer	1.22e-05	8.91e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—NRAS—thyroid cancer	1.22e-05	8.88e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—TP53—thyroid cancer	1.22e-05	8.88e-05	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—TP53—thyroid cancer	1.22e-05	8.88e-05	CbGpPWpGaD
Bromocriptine—HTR6—Signaling Pathways—AKT1—thyroid cancer	1.21e-05	8.82e-05	CbGpPWpGaD
Bromocriptine—HTR7—Signaling Pathways—AKT1—thyroid cancer	1.21e-05	8.81e-05	CbGpPWpGaD
Bromocriptine—HTR1D—Signaling Pathways—AKT1—thyroid cancer	1.2e-05	8.76e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—NRAS—thyroid cancer	1.2e-05	8.74e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—KRAS—thyroid cancer	1.19e-05	8.7e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling by GPCR—AKT1—thyroid cancer	1.19e-05	8.69e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—KRAS—thyroid cancer	1.19e-05	8.66e-05	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—HRAS—thyroid cancer	1.18e-05	8.6e-05	CbGpPWpGaD
Bromocriptine—HTR1B—Signaling Pathways—AKT1—thyroid cancer	1.18e-05	8.57e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—PPARG—thyroid cancer	1.18e-05	8.57e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—NRAS—thyroid cancer	1.17e-05	8.55e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—HRAS—thyroid cancer	1.17e-05	8.49e-05	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—HRAS—thyroid cancer	1.17e-05	8.49e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—PTGS2—thyroid cancer	1.16e-05	8.45e-05	CbGpPWpGaD
Bromocriptine—DRD4—Signaling Pathways—AKT1—thyroid cancer	1.16e-05	8.44e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—KRAS—thyroid cancer	1.16e-05	8.42e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—KRAS—thyroid cancer	1.14e-05	8.29e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—TP53—thyroid cancer	1.11e-05	8.09e-05	CbGpPWpGaD
Bromocriptine—HTR2B—Signaling Pathways—AKT1—thyroid cancer	1.11e-05	8.06e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—TP53—thyroid cancer	1.1e-05	8.01e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—NRAS—thyroid cancer	1.09e-05	7.95e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—TP53—thyroid cancer	1.06e-05	7.74e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—HRAS—thyroid cancer	1.06e-05	7.73e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—TP53—thyroid cancer	1.06e-05	7.7e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—HRAS—thyroid cancer	1.05e-05	7.66e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—KRAS—thyroid cancer	1.05e-05	7.64e-05	CbGpPWpGaD
Bromocriptine—DRD1—Signaling Pathways—AKT1—thyroid cancer	1.04e-05	7.6e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Metabolism—AKT1—thyroid cancer	1.04e-05	7.56e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—KRAS—thyroid cancer	1.03e-05	7.52e-05	CbGpPWpGaD
Bromocriptine—ADRA1D—Signaling Pathways—AKT1—thyroid cancer	1.03e-05	7.5e-05	CbGpPWpGaD
Bromocriptine—DRD3—Signaling Pathways—AKT1—thyroid cancer	1.03e-05	7.5e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—TP53—thyroid cancer	1.03e-05	7.49e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—HRAS—thyroid cancer	1.02e-05	7.4e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—PTEN—thyroid cancer	1.01e-05	7.37e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—TP53—thyroid cancer	1.01e-05	7.37e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—KRAS—thyroid cancer	1.01e-05	7.36e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—HRAS—thyroid cancer	1.01e-05	7.36e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—HRAS—thyroid cancer	9.83e-06	7.16e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—HRAS—thyroid cancer	9.67e-06	7.05e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—KRAS—thyroid cancer	9.39e-06	6.84e-05	CbGpPWpGaD
Bromocriptine—ADRB1—Signaling Pathways—AKT1—thyroid cancer	9.37e-06	6.83e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—TP53—thyroid cancer	9.32e-06	6.79e-05	CbGpPWpGaD
Bromocriptine—ADRA2B—Signaling Pathways—AKT1—thyroid cancer	9.29e-06	6.77e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—PTGS2—thyroid cancer	9.26e-06	6.74e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—TP53—thyroid cancer	9.17e-06	6.68e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—PPARG—thyroid cancer	9.08e-06	6.62e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—TP53—thyroid cancer	8.98e-06	6.54e-05	CbGpPWpGaD
Bromocriptine—HTR1A—Signaling Pathways—AKT1—thyroid cancer	8.97e-06	6.53e-05	CbGpPWpGaD
Bromocriptine—HTR2C—Signaling Pathways—AKT1—thyroid cancer	8.92e-06	6.5e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—HRAS—thyroid cancer	8.91e-06	6.5e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—HRAS—thyroid cancer	8.77e-06	6.39e-05	CbGpPWpGaD
Bromocriptine—ADRA2C—Signaling Pathways—AKT1—thyroid cancer	8.68e-06	6.32e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—HRAS—thyroid cancer	8.59e-06	6.26e-05	CbGpPWpGaD
Bromocriptine—ADRA1B—Signaling Pathways—AKT1—thyroid cancer	8.54e-06	6.22e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Metabolism—AKT1—thyroid cancer	8.43e-06	6.14e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—TP53—thyroid cancer	8.34e-06	6.08e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—PTEN—thyroid cancer	8.07e-06	5.88e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—HRAS—thyroid cancer	7.98e-06	5.81e-05	CbGpPWpGaD
Bromocriptine—DRD2—Signaling Pathways—AKT1—thyroid cancer	7.87e-06	5.74e-05	CbGpPWpGaD
Bromocriptine—HTR2A—Signaling Pathways—AKT1—thyroid cancer	7.75e-06	5.64e-05	CbGpPWpGaD
Bromocriptine—ADRA1A—Signaling Pathways—AKT1—thyroid cancer	7.58e-06	5.53e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—PTGS2—thyroid cancer	7.14e-06	5.2e-05	CbGpPWpGaD
Bromocriptine—ADRA2A—Signaling Pathways—AKT1—thyroid cancer	7.05e-06	5.13e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—PTEN—thyroid cancer	6.23e-06	4.54e-05	CbGpPWpGaD
Bromocriptine—ABCB1—Metabolism—AKT1—thyroid cancer	5.83e-06	4.25e-05	CbGpPWpGaD
Bromocriptine—CYP1A2—Metabolism—AKT1—thyroid cancer	4.65e-06	3.39e-05	CbGpPWpGaD
Bromocriptine—CYP3A4—Metabolism—AKT1—thyroid cancer	3.59e-06	2.62e-05	CbGpPWpGaD
